3b:{"drug_id":923818,"title":"Pantoprazole Sodium","ind":"FDA-Labeled Indications

Erosive esophagitis, Maintenance therapy - Gastroesophageal reflux disease
Erosive esophagitis - Gastroesophageal reflux disease
Gastric hypersecretion, Pathological
Zollinger-Ellison syndrome

Non-FDA Labeled Indications

Drug-induced gastrointestinal disturbance; Prophylaxis - Non-steroidal anti-inflammatory drug adverse reaction
Duodenal ulcer disease
Gastroesophageal reflux disease
Helicobacter pylori gastrointestinal tract infection
Recurrent gastrointestinal bleeding; Prophylaxis

","adult":"$3c","ped":"

General Dosage Information
- safety and efficacy not established in children
Erosive esophagitis - Gastroesophageal reflux disease
- (5 years and older; 15 to less than 40 kg) 20 mg orally once daily for up to 8 weeks
- (5 years and older; 40 kg and greater) 40 mg orally once daily for up to 8 weeks
Gastroesophageal reflux disease
- (5 to 11 years) Initial, 20 mg (0.6 to 0.9 mg/kg) orally once daily; increase to 40 mg once daily (1.2 mg/kg or greater) if symptoms do not improve (study dosage)

","side":"Common

Gastrointestinal:Abdominal pain (3%), Diarrhea (4%), Flatulence (4%)
Neurologic:Headache (5%)

Serious

Gastrointestinal:Atrophic gastritis, Clostridium difficile diarrhea
Hematologic:Thrombocytopenia (less than 1%)
Immunologic:Stevens-Johnson syndrome, Toxic epidermal necrolysis
Musculoskeletal:Disorder of muscle, Fracture of bone, Osteoporosis-related, Hip fracture, Rhabdomyolysis
Renal:Interstitial nephritis, acute

","prgnancy":"

Pantoprazole: B (FDA)
Pantoprazole: B3 (AUS)

","intermajer":"

Atazanavir (theoretical)
Bosutinib (theoretical)
Cilostazol (theoretical)
Citalopram (theoretical)
Dabrafenib (theoretical)
Dasabuvir (theoretical)
Dasatinib (theoretical)
Erlotinib (theoretical)
Eslicarbazepine Acetate (theoretical)
Gefitinib (theoretical)
Ketoconazole (theoretical)
Ledipasvir (theoretical)
Methotrexate (probable)
Mycophenolate Mofetil (established)
Nelfinavir (probable)
Nilotinib (theoretical)
Pazopanib (established)
Saquinavir (theoretical)
Topotecan (theoretical)
Vismodegib (theoretical)

","clinical":"

Advise patient that drug may increase risk for osteoporosis-related fractures of the hip, wrist, or spine with multiple daily doses that are continued for longer than a year.
Warn patient to report diarrhea that does not improve, especially with persistent watery stools, fever, and abdominal pain.
Drug may cause abdominal pain, nausea, diarrhea, vomiting, flatulence, dizziness, headaches, fever, rash, and arthralgia.
Injection form may cause injection site reactions (eg, thrombophlebitis, abscess).
Tell patient to immediately report signs/symptoms of hypomagnesemia (eg, dizziness, palpitations, tetany, seizures.
Instruct patient using delayed-release oral suspension to mix with 1 teaspoonful of apple juice or applesauce and take at least 30 minutes before a meal.
Counsel patient using nasogastric tube to mix delayed-release oral suspension with 2 teaspoonfuls of apple juice in syringe and take at least 30 minutes before a meal.

","admin":"$3d","interminor":"

Cranberry (probable)
Levothyroxine (probable)
Warfarin (probable)

","contra":"

Rilpivirine (theoretical)","clas":"Gastric Acid Secretion Inhibitor","mode":"Pantoprazole sodium is a proton pump inhibitor (PPI) that covalently binds to the (H(+), K(+))-ATPase enzyme system at the secretory surface of the gastric parietal cell. This action suppresses the final step in gastric acid production and leads to inhibition of both basal and stimulated acid secretion
"}

PANTO-ER (Pantoprazole Sodium - Enteric Coated Tablet 40 mg) – Full Drug Info.

SCIENTIFIC NAME

INDICATIONS

CLASSIFICATION

MECHANISM OF ACTION

CLINICAL USE

ADULT DOSE

PEDIATRIC DOSE

ADMINISTRATION

CONTRAINDICATIONS

SIDE EFFECTS

PREGNANCY

MAJOR INTERACTIONS

MINOR INTERACTIONS